This 2024 study assesses the diagnostic efficacy of a novel plasma phosphorylated tau 217 immunoassay in detecting Alzheimer disease pathology across three observational cohorts, examining its potential to enhance diagnostic accuracy and elucidate underlying pathophysiological mechanisms.